{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:59:37Z","timestamp":1793923177929,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010434","name":"\"la Caixa\u201d Foundation","doi-asserted-by":"publisher","award":["100010434"],"award-info":[{"award-number":["100010434"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ygyno.2020.06.495","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T01:49:13Z","timestamp":1595382553000},"page":"614-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer"],"prefix":"10.1016","volume":"158","author":[{"given":"Martina Aida","family":"Angeles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Rychlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Cabarrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Guyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"P\u00e9rez-Benavente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Querleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Mery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gw\u00e9na\u00ebl","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.06.495_bb0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0015","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0020","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1245\/s10434-015-5051-9","article-title":"What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian Cancer?","volume":"23","author":"Chiva","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0025","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0030","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American society of clinical oncology clinical practice guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0035","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2019.07.011","article-title":"A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy","volume":"154","author":"Bartels","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0040","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0050","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.18632\/oncotarget.23808","article-title":"The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies","volume":"9","author":"Qin","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2020.06.495_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000485618","article-title":"Platinum-based neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma international federation of gynecology and obstetrics stages IIIc and IV: a systematic review and meta-analysis","volume":"83","author":"Xiao","year":"2018","journal-title":"Gynecol. Obstet. Investig."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0060","doi-asserted-by":"crossref","first-page":"35914","DOI":"10.1038\/srep35914","article-title":"Neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: a meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0065","doi-asserted-by":"crossref","first-page":"330","DOI":"10.23736\/S0026-4806.19.06078-6","article-title":"Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis","volume":"110","author":"Chiofalo","year":"2019","journal-title":"Minerva Med."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0075","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ejso.2006.03.002","article-title":"Quantitative prognostic indices in peritoneal carcinomatosis","volume":"32","author":"Gilly","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2007.05.032","article-title":"A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model","volume":"107","author":"Aletti","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0085","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1245\/s10434-015-5069-z","article-title":"Surgical complexity impact on survival after complete cytoreductive surgery for advanced ovarian cancer","volume":"23","author":"Martinez","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0100","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies","volume":"16","author":"Kang","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.06.495_bb0110","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"29","author":"Reuss","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.06.495_bb0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","article-title":"A critique of surgical cytoreduction in advanced ovarian cancer","volume":"78","author":"Covens","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0120","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","article-title":"Evolution of platinum resistance in high-grade serous ovarian cancer","volume":"12","author":"Cooke","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3802\/jgo.2019.30.e81","article-title":"Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?","volume":"30","author":"Yoneoka","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000449203","article-title":"Does the number of neoadjuvant chemotherapy cycles before interval debulking surgery influence survival in advanced ovarian cancer?","volume":"91","author":"Akladios","year":"2016","journal-title":"Oncology."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejso.2018.01.097","article-title":"Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer","volume":"44","author":"Phillips","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0140","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejogrb.2011.07.014","article-title":"Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?","volume":"159","author":"Stoeckle","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2014.09.002","article-title":"Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer","volume":"135","author":"Colombo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0150","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00404-016-4256-x","article-title":"The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc\u2013IV high-grade serous ovarian cancer","volume":"295","author":"Xu","year":"2017","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0155","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2009.11.022","article-title":"The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum","volume":"116","author":"Zivanovic","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0165","series-title":"Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial","volume":"23","author":"Crawford","year":"2005"},{"key":"10.1016\/j.ygyno.2020.06.495_bb0170","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0175","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00404-016-4265-9","article-title":"The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"295","author":"Turnbull","year":"2017","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jviscsurg.2019.12.002","article-title":"A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer","volume":"157","author":"Liberale","year":"2020","journal-title":"J. Visc. Surg."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039415","article-title":"Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer","volume":"7","author":"Rafii","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.06.495_bb0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2010.05.031","article-title":"The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas","volume":"119","author":"Chi","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.495_bb0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2009.03.011","article-title":"Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review","volume":"114","author":"Gerestein","year":"2009","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:26Z","timestamp":1758772346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820323210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090825820323210"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.495","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}